Rapid Briefs
VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.
Filtered signal trail
Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.
Why now
The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.
NEJM published first pediatric data for exa-cel in children under 12 with sickle cell disease or transfusion-dependent beta thalassemia.
Why now
CRISPR medicine is moving younger, raising the early-intervention question before years of organ damage accumulate.
A one-time in-body CRISPR infusion cut hereditary angioedema attacks by 87% versus placebo in a global Phase 3 trial, but it is not approved yet.
Why now
In vivo CRISPR crossing into large double-blind Phase 3 evidence is a major platform milestone.
Epicrispr says its one-time EPI-321 therapy increased lean muscle volume in three patients with facioscapulohumeral muscular dystrophy.
Why now
Epigenetic editing is a new category readers will share, especially with early muscle-volume signals.
A young actress and Spelman graduate is preparing for Casgevy after years of sickle-cell pain crises, but her treatment story is still pre-infusion.
Why now
McKenzie's story lets VV track a Casgevy journey from collection and manufacturing through infusion, rather than only covering the post-treatment headline.
Sickle cell disease blocked Daniel Cressy's path to becoming a commercial pilot. After Casgevy gene therapy, the 23-year-old is working toward that future again.
Why now
A patient-level milestone is moving gene therapy from approval news into real-world care in Louisiana and national coverage.
A new FDA draft guidance and recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
